Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru

Abstract Objective To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. Results There were 279 M. tuberculosis isolates from the two cohorts (200...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alvaro Schwalb, Rodrigo Cachay, Ericka Meza, Tatiana Cáceres, Amondrea Blackman, Fernanda Maruri, Timothy R. Sterling, Eduardo Gotuzzo
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Levofloxacin Moxifloxacin Ofloxacin Drug resistance Medicine R Biology (General) QH301-705.5 Science (General) Q1-390
Acceso en línea:	https://doaj.org/article/7cd252c8f6014d1aa079c1efedb2ff40
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7cd252c8f6014d1aa079c1efedb2ff40
record_format	dspace
spelling	oai:doaj.org-article:7cd252c8f6014d1aa079c1efedb2ff402021-11-21T12:28:02ZFluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru10.1186/s13104-021-05832-01756-0500https://doaj.org/article/7cd252c8f6014d1aa079c1efedb2ff402021-11-01T00:00:00Zhttps://doi.org/10.1186/s13104-021-05832-0https://doaj.org/toc/1756-0500Abstract Objective To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. Results There were 279 M. tuberculosis isolates from the two cohorts (2004–2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0–0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0–0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru.Alvaro SchwalbRodrigo CachayEricka MezaTatiana CáceresAmondrea BlackmanFernanda MaruriTimothy R. SterlingEduardo GotuzzoBMCarticleLevofloxacinMoxifloxacinOfloxacinDrug resistanceMedicineRBiology (General)QH301-705.5Science (General)Q1-390ENBMC Research Notes, Vol 14, Iss 1, Pp 1-4 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Levofloxacin Moxifloxacin Ofloxacin Drug resistance Medicine R Biology (General) QH301-705.5 Science (General) Q1-390
spellingShingle	Levofloxacin Moxifloxacin Ofloxacin Drug resistance Medicine R Biology (General) QH301-705.5 Science (General) Q1-390 Alvaro Schwalb Rodrigo Cachay Ericka Meza Tatiana Cáceres Amondrea Blackman Fernanda Maruri Timothy R. Sterling Eduardo Gotuzzo Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
description	Abstract Objective To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. Results There were 279 M. tuberculosis isolates from the two cohorts (2004–2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0–0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0–0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru.
format	article
author	Alvaro Schwalb Rodrigo Cachay Ericka Meza Tatiana Cáceres Amondrea Blackman Fernanda Maruri Timothy R. Sterling Eduardo Gotuzzo
author_facet	Alvaro Schwalb Rodrigo Cachay Ericka Meza Tatiana Cáceres Amondrea Blackman Fernanda Maruri Timothy R. Sterling Eduardo Gotuzzo
author_sort	Alvaro Schwalb
title	Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
title_short	Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
title_full	Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
title_fullStr	Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
title_full_unstemmed	Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
title_sort	fluoroquinolone susceptibility in first-line drug-susceptible m. tuberculosis isolates in lima, peru
publisher	BMC
publishDate	2021
url	https://doaj.org/article/7cd252c8f6014d1aa079c1efedb2ff40
work_keys_str_mv	AT alvaroschwalb fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu AT rodrigocachay fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu AT erickameza fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu AT tatianacaceres fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu AT amondreablackman fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu AT fernandamaruri fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu AT timothyrsterling fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu AT eduardogotuzzo fluoroquinolonesusceptibilityinfirstlinedrugsusceptiblemtuberculosisisolatesinlimaperu
_version_	1718419015050723328

Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru

Ejemplares similares